NMPA accepts clinical trial application for monkeypox vaccine
chinadaily.com.cn |
Updated: 2023-07-14 19:44
Share
Share - WeChat
The National Medical Products Administration (NMPA) has, on Thursday, officially accepted the clinical trial application for the replication-deficient monkeypox vaccine developed by China National Pharmaceutical Group Corporation (Sinopharm) Beijing Institute of Biological Products.
- Mainland reiterates 1992 Consensus as foundation for resuming cross-Strait dialogue
- PLA drone training near China's Dongsha island lawful: spokesperson
- China's top political advisor stresses boosting new five-year plan off to a good start
- Over 1,000 media professionals register to cover Asian Beach Games in Sanya
- Around 4,000 cyberattack incidents originating from Taiwan investigated in 2025
- Sanya hosts international dragon, lion dance competition
